-

Owkin Announces MSIntuit® CRC v2, a Next-Generation AI Diagnostic Aimed at Transforming the Detection and Treatment of Colorectal Cancer

  • MSIntuit® CRC v2 is designed to streamline MSI testing for patients with colorectal cancers (CRC), now including analysis from biopsy samples
  • A Research Use Only (RUO) version will launch on Roche’s navify® Digital Pathology enterprise software, an application for the pathologist’s workflow aimed to support pathologists and scientists in cancer research and diagnosis
  • Owkin is collaborating with Roche on its digital pathology open environment to help advance cancer diagnostics through AI and elevate the capabilities of pathologists and scientists

PARIS--(BUSINESS WIRE)--Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development, and diagnostics has announced MSIntuit® CRC v21, a next-generation AI solution. Aimed at transforming the detection and treatment of colorectal cancer (CRC), MSIntuit® CRC v2 will initially launch as an RUO version in the US on Roche’s navify® Digital Pathology enterprise software.

MSIntuit® CRC v2 builds upon the success of the CE-IVD-certified MSIntuit® CRC, integrating cutting-edge machine learning models developed by Owkin with Roche's unparalleled expertise in oncology diagnostics. MSIntuit® CRC v2 will incorporate analysis from resections, and now biopsies, addressing a critical need within pathologists’ workflows.

This latest version features a new architecture with advanced machine learning models significantly enhancing model performance. It also introduces improved staining techniques, including H&E (Hematoxylin and Eosin) and HES (Hematoxylin, Eosin, and Saffron), further refining the accuracy and reliability of the product, and expanding access of the solution to more labs.

Meriem Sefta, PhD, Chief Diagnostics Officer of Owkin, said: "We are thrilled to bring the next innovations in MSIntuit® CRC to pathology labs, marking a significant advancement in the field of medical diagnostics. This innovation represents our commitment to pushing the boundaries of artificial intelligence in healthcare. By leveraging cutting-edge AI technology, we aim to provide more accurate diagnostic tools that will empower pathologists and oncologists to make more informed decisions. Our goal is to help deliver highly personalized treatment plans, improving patient outcomes and ensuring that each individual receives the most precise care tailored to their unique medical needs. This is just one step forward in transforming the future of patient care through technology-driven solutions and we look forward to expanding our collaboration with Roche Diagnostics in pursuit of this essential mission."

These tools are designed to enhance pathology insights, helping benefit cancer patients through precision medicine and enabling targeted treatments. The RUO version of MSIntuit® CRC v2 will soon be available in the US on Roche’s navify® Digital Pathology enterprise software, with additional platforms to come.

About Owkin

Owkin is the first end-to-end AI biotech company on a mission to understand complex biology and ensure every patient gets the right treatment. We identify precision therapeutics, de-risk and accelerate clinical trials, and develop diagnostics using AI trained on world-class patient data through privacy-enhancing technologies. We merge wet lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation in oncology, cardiovascular disease, and immunity and inflammation. Owkin also founded MOSAIC, the world’s largest spatial multi-omics atlas for cancer research across nine cancer indications. Owkin has raised over $300 million through investments from leading biopharma companies, including Sanofi and BMS, and venture funds like F-Prime, GV and Bpifrance, among others.

1 In the US, MSIntuit CRC is under development and currently For Research Use Only. Not for use in diagnostic procedures. In Europe, MSIntuit CRC is under development and will be submitted for CE-IVDR marking.

Contacts

owkin@brands2life.com

Industry:

Owkin

Release Versions
EnglishSpanish (Summary)GermanFrenchItalian (Summary)Dutch (Summary)

Contacts

owkin@brands2life.com

More News From Owkin

Owkin Announces International Validation Results of BRCAura: AI-Driven Screening for gBRCA Mutations Directly From Pathology Slides

PARIS--(BUSINESS WIRE)--Owkin shares promising validation results for BRCAura RUO, a clinical-grade research-use-only AI product designed to screen for germline BRCA1/2 mutations (gBRCAm) directly from digitized breast cancer pathology slides. Breast cancer remains the leading cause of cancer-related deaths among women worldwide. Identifying patients with germline BRCA1/2 mutations is essential for guiding targeted treatment decisions, but testing is not always consistently offered to eligible...

Université Paris-Saclay and Owkin: A Unique Alliance to Propel University Medical Research to the Top of the European Rankings Through AI

PARIS--(BUSINESS WIRE)--Université Paris-Saclay and Owkin announce the signing of a memorandum of understanding to explore the potential of K Pro Free - Owkin’s AI co-pilot for biology - for use by Paris-Saclay. K Pro Free will now be available to the entire Université Paris-Saclay community, and in particular teachers, researchers and doctoral students working in the biomedical sciences. The partnership includes workshops, training sessions and events designed to promote the discovery and adop...

Owkin Unveils Europe’s First Pan-European Agentic Infrastructure for Biology at the Franco-German Digital Sovereignty Summit

BERLIN--(BUSINESS WIRE)--At today’s Franco-German Summit on Digital Sovereignty in Berlin, Owkin, together with leading academic partners Gustave Roussy (France) and Charité Comprehensive Cancer Center (Germany), announced a landmark initiative to build the first pan-European agentic infrastructure to make biological data AI-ready, as a key step towards biological super intelligence. The project aims to develop and deploy modern AI methods to support biological research and drug development. An...
Back to Newsroom